We aimed to explore the interaction among lncRNA MALAT1, miR-129 and SOX2. 
Long non-coding RNAs (lncRNAs), a group of non-protein coding transcripts longer than 200 nucleotides, play a key role in many types of malignant tumours, including glioma. 8 LncRNAs may function as competing endogenous RNAs (ceRNAs) to modulate miRNA expressions. 9 Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is an lncRNA with a length of approximately 8000-nt. 8 Wang et al revealed that MALAT1 was aberrantly expressed in carcinoma cells. 10 Ma et al 11 found that MALAT1 was up-regulated in glioma tissues and correlated with the progression of glioma. However, the molecular mechanism of MALAT1 in glioma cells remains unknown.
MicroRNAs (miRNAs) are short single-stranded RNA molecules which function as a critical modulator in gene expression by wholly or partially binding to corresponding mRNAs. 12 MiRNAs play a crucial role in the progression of various cancers, such as osteosarcoma 12 and glioma. 13 MiR-129 is a miRNA family mainly composed of miR-129-3p, miR-129-2-3p and miR-129-5p. 14 Previous researches have already demonstrated that miR-129-5p acted as a tumour inhibitor in multiple cancers such as ovarian cancer, 15 breast cancer 16 and also glioma. 17 Chen et al 18 found that Notch-1/ E2F7/Beclin-1 axis was regulated and further the viability of malignant glioma cells could be impaired by up-regulation of miR-129. However, the role of miR-129 in glioma stem cells has not been elucidated so far.
SRY (sex determining region Y)-box 2 (SOX2) is revealed as a
stemness marker in glioma 19 and a transcription factor highly associated with pluripotency. 20 Current study investigated the relationship between SOX2 and miR-129 to further elucidate the molecule network of miR-129 in glioma stem cells progression. Activated SOX2 expression maintained stemness and self-renewal of GSCs. 21 
SOX2
is associated with GBM stem-like phenotype which is more resistant to c-radiation. 22 Therefore, SOX2 expression changes are significant for GSC stemness maintainment.
This study hypothesized the promoter role of lnc MALAT1 in glioma and validated its effect in both in vivo and in vitro experiments.
MALAT1 was suspected to bind to miR-129 which target at SOX2, an oncogene, and their interaction was depicted in this study. By illustrating the underlying mechanism that facilitated glioma progression, this study may contribute to the application of glioma target therapy. Human Genome U133 Plus 2.0 Array) was downloaded and processed as well for matching probes and corresponding gene symbols.
| MATERIALS AND METHODS

| Clinical specimens
Expressions of lncRNAs in 14 conventional glioma cell lines (G121,   G84, G120, G61, G112, G130, U118MG, SF268, G124, G118, G142, G44, SW1783 and G22) and 5 glioma stem-like cell lines (GS01, GS02, GS03, GS04 and GS05) were analysed using unpaired T-test method in the LIMMA package and the obtained P values were adjusted with Benjamini-Hochberg method. A volcano plot filtering (fold change > 4, adjusted P-value < .01) was drawn and all the differentially expressed lncRNAs were listed in the heat map.
| QRT-PCR
The extraction of total RNA was implemented by Trizol reagent (Invitrogen, USA), and the purity and concentration of RNA were detected by NanoDrop 1000 (Nanodrop Technologies Inc., USA).
First Strand cDNA Synthesis Kit (Biochemical Industry Inc., USA) was used for the reverse transcription according to the instructions.
Quantitative PCR was conducted through Bio-Rad MiniOpticon realtime PCR system, using Maxima SYBR Green qPCR Master Mix (2X) kit (Fermentas, Burlington, Canada) for amplified detection according to the manual. GAPDH was deemed as a reference gene of SOX2 and MALAT1, while U6 was an internal control of miR-129. The relative expression levels of MALAT1, miR-129 and SOX2 were determined by using the 2 ÀDDCT method. The primers were synthesized by Sangon Biotech (Shanghai, China). The detailed primers were exhibited in Table 1 .
| Western blot
The isolation of total protein from tissues and protein concentration measurement were performed by using RIPA lysis buffer and BCA protein concentration kit (Beyotime, Shanghai, China 
| EdU assay
Transfected glioma stem cells were cultured in 96-well plates.
Briefly, glioma stem cells were incubated with EdU labelling medium at moderate concentration for 2 hours. The cells were then fixed with 0.5% TritonX-100 in PBS (100 lL) for 25 minutes, and stained with 100 lL Apollo dye solution (Ribobio) for 30 minutes at room temperature. The cells were subsequently stained using DAPI (Invitrogen) and incubated for half an hour. The percentage of EdU positive cells was calculated using ImageJ software.
| Sphere formation assay
Glioma stem cells were seeded into 6-well plate at 5 
| Xenograft mouse model
| Statistical analysis
Statistical analyses were performed through GraphPad Prism 6.0 (GraphPad Software, San Diego, California, USA). All quantitative data are presented as means AE standard deviation (SD). Differences between groups were compared using Student's t-test while comparison in multiple groups was practiced with one-way ANOVA. Benjamini-Hochberg was used to adjust multiple testing for selection of differentially expressed lncRNAs. Statistical significance was based on P value < .05. Table 3 . After we obtained glioma stem cells from glioma cells, qRT-PCR was utilized to measure the expression level of MALAT1.
As shown in Figure 1B ,C, MALAT1 expression in glioma stem cells was remarkably higher than compared with non-stem cells (P < .0001). G121  G84  G120  G61  G112  G130  U118MG  SF268  G124  G118  G142  G44  SW1783  G22  GS01  GS02  GS03  GS04  GS05   TBX2−AS1  LINC00461  SNHG9  UG0898H09  SNHG15  MALAT1  PWAR6  LINC01465  LINC00936  LINC00526  DLEU2  ATP13A4−AS1  URB1−AS1  ILF3−AS1  SEPT7−AS1  CCEPR  ELOVL2−AS1  TRAF3IP2−AS1  SNORD3A  TRDC  TRDV3  BRWD1−IT2  BOLA3−AS1  PEG3−AS1  MINCR  BAALC−AS2  ENO1−AS1  CAHM  YTHDF3−AS1  FGF14−AS2  TOLLIP−AS1  IDH1−AS1  GS1−124K5.4  LINC00665  ARHGAP5−AS1  LINC01003  PAXIP1−AS1  LINC01315  PRKAG2−AS1  LINC01158  LINC00938  ZNF793−AS1  GBAT2  NEAT1  STX17−AS1  MSC−AS1  PSMD5−AS1  LOXL1−AS1  MMP24−AS1  SNHG16  LINC00152  AGAP2−AS1  EBLN3  LINC01116  GAS5  LINC01296  IGHG1  SERTAD4− 
| MALAT1 promotes the growth of glioma stem cells
CD133 CD24
A B C
F I G U R E 1 MALAT1 is highly expressed in glioma stem cells. A, The differentially expressed lncRNAs in glioma stem cells (including GS01, GS02, GS03, GS04 and GS05) and glioma tissue cells (including G121, G84, G120, G61, G112, G130, U118MG, SF268, G124, G118, G142, G44, SW1783 and G22) were screened through microarray analysis. MALAT1 was found to be significantly up-regulated in GSCs. B, Glioma stem cells were isolated from glioma cancer cells with flow cytometry and those with CD144 + CD24 À markers were considered as GSCs. C, UTR and miR-129 mimics group was considerably weaker (Figure 3D ,E, P < .01). Additionally, we also examined the expression of miR-129 using qRT-PCR after si-MALAT1 transfection. As shown in Figure 3F , the expression level of miR-129 was significantly up-regulated in si-MALAT1#1 and si-MALAT1#2 groups in comparison with NC group (both P < .01).
| MiR-129 restrains the propagation of glioma stem cells
The 
| SOX2 is a direct target of miR-129
Previous studies ever identified that SOX2 was required for cancer cell line progression in lung and esophageal squamous carcinoma, highlighting the importance of SOX2 as a lineage-survival oncogene. 27 High SOX2 expression has been associated with several human solid tumours, including glioma. 28 The present study evaluated that expression of SOX2 mRNA in glioma stem cells was significantly higher than that in glioma cells detected by qRT-PCR ( Figure 5A , P < .001). Tar Emerging evidence has indicated that lncRNA could sponge miRNA and regulate the functions of miRNAs. 31 Previous studies also indicated that MALAT1 presented various functions as miRNA sponges in different cancers. For example, MALAT1 promoted malignant melanoma growth and metastasis by sponging miR-22. 32 In our research, MALAT1 bound to miR-129 directly to suppress its expression, which was firstly studied.
Earlier studies have reported that miR-129-2 suppressed glioma by targeting HMGB1 in glioma in an DNA methylation way. 33 MiR-129 also impair human malignant glioma progression via autophagic flux enhancement by regulating a novel Notch-1/ E2F7/Beclin-1 axis. 18 Kang et al 34 revealed that miR-129-2 suppressed proliferation of esophageal carcinoma cells through down-regulation of SOX4 expression. Elevated SOX2 enforces glioblastoma stem cell identity. 35 High miR-21/low SOX2 axis was capable of classifying patients with longer survival. 36 We also diagnosed miR-129 as a tumour suppressor via SOX2 modulation firstly in glioma tumorigenesis. Besides, the MALAT1/miR-129/SOX4 was of great significance in present molecular system investigation.
As an important pluripotent marker of stem cells, SOX2 has been recognized as serving a crucial role in maintaining the properties of cancer stem cells. 37 According to the study of Wang et al 38 SOX2 was considered as a predictor of survival in gastric cancer to inhibit cell proliferation and metastasis. Chen et al also revealed that silencing of SOX2 could regulate the apoptosis rate of human lung cancer cells. C-E, CCK-8 assay and EdU assay showed that cell proliferation of glioma stem cells were significantly attenuated in miR-129 overexpression group but remarkably enhanced in miR-129 inhibitor group compared with NC group. F-G, The sphere formation assay results also revealed that the sphere formation efficiency of glioma stem cells in miR-129 mimics group was significantly lower than that in NC group, while the cells transfected with miR-129 inhibitor presented higher sphere formation efficiency in comparison with NC group determined by sphere formation assay. Scale bar, 100 lm. **P < .01. ***P < .001, ****P < .0001, compared with NC group 
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